Abstract
Objective To prepare 18F-5-fluoro-N-(2-(diethylamino)ethyl) picolinamide (18F-5-FPN) and evaluate its binding affinity with melanin. Methods 5-bromo-N-(2-(diethylamino)ethyl)picolinamide (precursor) was synthesized and the structure was characterized by ultraviolet (UV), nuclear magnetic resonance (NMR) and mass spectrometry. 18F-5-FPN was prepared with FX-XN module through nucleophilic substitution reaction. The product was purified and identified by HPLC. The binding specificity of 18F-5-FPN with melanin was demonstrated by in vitro study of cellular uptake, and in vivo static PET imaging of pigmented B16F10 and amelanotic A375m allografts. Biodistribution study was performed to evaluate the pharmacokinetics of 18F-5-FPN in vivo. Two-sample t test was used for data analysis. Results The structure of precursor was characterized by UV, 1H NMR, 13C NMR and mass spectrometry. 18F-5-FPN was successfully prepared with radiochemical yield of 5%-8%, radiochemical purity >95% and the specific activity of 100-120 GBq/μmol. The cell uptake study showed that the uptakes of 18F-5-FPN in B16F10 cells at 30, 60 and 120 min ((9.80±0.46)%, (10.34±0.32)%, (7.27±0.26)%) were significantly higher than those in A375m cells ((1.36±0.14)%, (1.75±0.12)%, (1.54±0.09)%; t=30.3, 46.8, 38.4, all P<0.05), and the optimal uptakes were observed at 60 min for both cells. In static PET imaging, the tumors in B16F10-bearing mice were clearly visible with the uptake value of (18.20±3.21) %ID/g and the T/B ratio of 19.17±10.03 at 1 h postinjection, while no tumor uptake was seen in A375m-bearing mice. The main clearance pathway of 18F-5-FPN was the renal system, which cleared the unbound tracer rapidly. Conclusions 18F-5-FPN can specifically target the melanin in vitro and in vivo with favorable pharmacokinetics and good T/B ratio. 18F-5-FPN may be an ideal molecular probe for diagnosis of malignant melanoma. Key words: Formamides; Isotope labeling; Fluorine radioisotopes; Tomography, emission-computed; Melanoma; Mice
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Chinese Journal of Nuclear Medicine and Molecular Imaging
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.